Clinical trial · Interventional
Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC
Evaluation of the Oncomine Precision Assay GX Method for Genotyping Circulating Tumor DNA in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This interventional clinical study evaluates the clinical utility and feasibility of the Oncomine Precision Assay GX method for genotyping circulating tumor DNA (ctDNA) in patients with advanced non-small cell lung cancer (NSCLC). Participants with advanced NSCLC undergo peripheral blood sampling as part of the study intervention. Circulating tumor DNA is analyzed using the Oncomine Precision Assay GX platform. Molecular findings obtained from liquid biopsy are compared with available standard diagnostic results from tumor tissue or other clinically indicated molecular testing methods. The aim of the study is to evaluate the feasibility, diagnostic performance, and clinical applicability of ctDNA genotyping using the Oncomine Precision Assay GX method in a real-world clinical setting and to assess its potential role in routine molecular diagnostics of advanced NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oncomine Precision Assay GX ctDNA Testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Oncomine Precision Assay GX ctDNA Testing
- description
- Participants with advanced non-small cell lung cancer undergo peripheral blood sampling for circulating tumor DNA (ctDNA) analysis using the Oncomine Precision Assay GX method. The assay is evaluated for feasibility and diagnostic performance in routine clinical practice and compared with standard molecular testing results.
- interventionNames
- Diagnostic Test: Oncomine Precision Assay GX ctDNA Testing
Primary outcomes (1)
- measure
- Feasibility Rate of ctDNA Genotyping Using Oncomine Precision Assay GX
- timeFrame
- From baseline blood sampling through study completion (up to 19 months)
- description
- Feasibility is assessed as the proportion of collected blood samples with successful circulating tumor DNA (ctDNA) extraction and successful molecular genotyping using the Oncomine Precision Assay GX method in patients with advanced non-small cell lung cancer (NSCLC).
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC) * Planned or ongoing systemic treatment for advanced NSCLC according to standard clinical practice * Availability of blood sample for circulating tumor DNA (ctDNA) analysis * Ability to understand the study procedures and provide written informed consent Exclusion Criteria: * Inability or unwillingness to provide written informed consent * Insufficient blood sample for ctDNA analysis * Any medical condition that, in the investigator's opinion, would interfere with participation or interpretation of results
References
Publications (0)
Data not yet available